<PAGE> 1
EXHIBIT 99.01
The Private Securities Litigation Reform Act of 1995 (the "Act") provides a
"safe harbor" for "forward-looking statements" (as defined in the Act). The
Company's Form 10-K, the Company's Annual Report to Shareholders, any Form 10-Q
or any Form 8-K of the Company, the Company's press releases, or any other
written or oral statements made by or on behalf of the Company, may include or
incorporate by reference forward-looking statements which reflect the Company's
current view (as of the date such forward-looking statement is first made) with
respect to future events, prospects, projections or financial performance. These
forward-looking statements are subject to certain uncertainties and other
factors that could cause actual results to differ materially from those made,
implied or projected in such statements. These uncertainties and other factors
include, but are not limited to:
- uncertainties relating to general economic conditions;
- the loss of one or more key customer or supplier relationships, such as
pharmaceutical and medical-surgical manufacturers for which alternative
supplies may not be available;
- challenges associated with integrating our information systems with
those of our customers;
- potential liabilities associated with warranties of our information
systems, and the malfunction or failure of our information systems or
those of third parties with whom we do business, such as malfunctions
or failures associated with date-related issues and disruption to
internet-related operations;
- the costs and difficulties related to the integration of recently
acquired businesses;
- changes to the presentation of financial results and position resulting
from adoption of new accounting principles or upon the advice of our
independent auditors or the staff of the SEC;
- changes in the distribution or outsourcing pattern for pharmaceutical
and medical-surgical products and services, including an increase in
direct distribution or a decrease in contract packaging by
pharmaceutical manufacturers;
- changes in government regulations or our failure to comply with those
regulations;
- the costs and other effects of legal and administrative proceedings;
- injury to person or property resulting from our manufacturing,
packaging, repackaging, drug delivery system development and
manufacturing, information systems, or pharmacy management services;
- competitive factors in our healthcare service businesses, including
pricing pressures;
- unforeseen changes in our existing agency and distribution
arrangements;
- the continued financial viability and success of our customers,
suppliers, and franchisees;
- difficulties encountered by our competitors, whether or not we face the
same or similar issues;
- technological developments and products offered by competitors;
- failure to retain or continue to attract senior management or key
personnel;
- risks associated with international operations, including fluctuations
in currency exchange ratios and implementation of the Euro currency;
- costs associated with protecting our trade secrets and enforcing our
patent, copyright and trademark rights, and successful challenges to
the validity of our patents, copyrights or trademarks;
- difficulties or delays in the development, production, manufacturing,
and marketing of new products and services;
- strikes or other labor disruptions;
- labor and employee benefit costs;
- pharmaceutical and medical-surgical manufacturers' pricing policies and
overall drug price inflation;
- changes in hospital buying groups or hospital buying practices; and
- other factors described in this document or the documents we file with
the Securities and Exchange Commission.
The words "believe", "expect", "anticipate", "project", and similar expressions
identify "forward-looking statements", which speak only as of the date the
statement was made. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
